{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:38:03Z","timestamp":1790793483272,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":34,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.msard.2022.104169","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:05:03Z","timestamp":1662703503000},"page":"104169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon"],"prefix":"10.1016","volume":"67","author":[{"given":"Mirna","family":"Matni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salam","family":"Koussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaker","family":"Khamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora","family":"Fleifel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahdak","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omneya","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"346","key":"10.1016\/j.msard.2022.104169_bib0001","first-page":"1","article-title":"A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis","volume":"13","author":"Acaster","year":"2013","journal-title":"BMC Health Serv. Res."},{"issue":"8","key":"10.1016\/j.msard.2022.104169_bib0002","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1080\/03007995.2019.1585779","article-title":"Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing\u2013remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatmen","volume":"35","author":"Berardi","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.msard.2022.104169_bib0004","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2022.104169_bib0005","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"12","key":"10.1016\/j.msard.2022.104169_bib0006","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. J."},{"issue":"4","key":"10.1016\/j.msard.2022.104169_bib0007","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jval.2016.01.002","article-title":"Health utilities for multiple sclerosis","volume":"19","author":"Hawton","year":"2016","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.msard.2022.104169_bib0008","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10198-015-0728-3","article-title":"Multiple sclerosis: relapses, resource use, and costs","volume":"17","author":"Hawton","year":"2016","journal-title":"Eur. J. Health Econ."},{"issue":"7","key":"10.1016\/j.msard.2022.104169_bib0009","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","article-title":"Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England","volume":"21","author":"Hettle","year":"2018","journal-title":"J. Med. Econ."},{"issue":"4","key":"10.1016\/j.msard.2022.104169_bib0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000431042","article-title":"Multiple sclerosis epidemiology in Middle East and North Africa: a systematic review and meta-analysis","volume":"44","author":"Heydarpour","year":"2015","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.msard.2022.104169_bib0011","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458512441566","article-title":"Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries","volume":"18","author":"Karampampa","year":"2012","journal-title":"Mult. Scler. J."},{"issue":"11","key":"10.1016\/j.msard.2022.104169_bib0012","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2022.104169_bib0013","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.msard.2022.104169_bib0014","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s10198-014-0649-6","article-title":"Health state utilities associated with attributes of treatments for hepatitis C","volume":"16","author":"Matza","year":"2015","journal-title":"Eur. J. Health Econ."},{"issue":"5","key":"10.1016\/j.msard.2022.104169_bib0015","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.104169_bib0003","unstructured":"European Medicines Agency. Mavenclad: EPAR - Summary for the Public. 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mavenclad-epar-summary-public_en.pdf."},{"key":"10.1016\/j.msard.2022.104169_bib0016","unstructured":"Multiple Sclerosis Trust. How common is multiple sclerosis?. 2021. Available from: https:\/\/mstrust.org.uk\/a-z\/how-common-multiple-sclerosis#targetText=Multiple sclerosis in the UK."},{"key":"10.1016\/j.msard.2022.104169_bib0017","unstructured":"National Institute for Health and Care Excellence (NICE). Cladribine for treating relapsing-remitting multiple sclerosis - Technology appraisal guidance [TA616]. 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/ta616."},{"issue":"1","key":"10.1016\/j.msard.2022.104169_bib0019","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","article-title":"The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK","volume":"10","author":"Orme","year":"2007","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.msard.2022.104169_bib0020","doi-asserted-by":"crossref","first-page":"A652","DOI":"10.1016\/j.jval.2016.09.1756","article-title":"Cost-effectiveness of apixaban for the treatment of atrial fibrillation patients in the Kingdom of Saudi Arabia","volume":"19","author":"Osenenko","year":"2016","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.msard.2022.104169_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2013-004073","article-title":"UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model","volume":"4","author":"Palace","year":"2014","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.msard.2022.104169_bib0022","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1474-4422(15)00018-6","article-title":"Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK multiple sclerosis risk sharing scheme at 6 years: a clinical cohort study with natural history comparator","volume":"14","author":"Palace","year":"2015","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.msard.2022.104169_bib0023","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","article-title":"The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations","volume":"264","author":"Pardo","year":"2017","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.104169_bib0024","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis","volume":"15","author":"Scolding","year":"2015","journal-title":"Pract. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2022.104169_bib0025","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.neurol.2012.12.002","article-title":"LSN MS guidelines for the management of multiple sclerosis","volume":"169","author":"Shatila","year":"2013","journal-title":"Rev. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2022.104169_bib0026","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","article-title":"Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing\u2013remitting multiple sclerosis","volume":"34","author":"Siddiqui","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.msard.2022.104169_bib0027","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1524-4733.2008.00485.x","article-title":"Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the medicare population","volume":"12","author":"Tappenden","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2022.104169_bib0018","unstructured":"Olek MJ, Mowry E. Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults. 2022. Available from: https:\/\/www.uptodate.com\/contents\/initial-disease-modifying-therapy-for-relapsing-remitting-multiple-sclerosis-in-adults?search=initial-disease-modifying-therapy-for-relapsing-remitting-multiple-sclerosis-in-adults.&source=search_result&selectedTitle=1\u223c150&usage_type=default&display_rank=1."},{"key":"10.1016\/j.msard.2022.104169_bib0028","article-title":"Cost effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis","author":"Tappenden","year":"2001","journal-title":"Final Report to the National Institute for Clinical Excellence"},{"key":"10.1016\/j.msard.2022.104169_bib0029","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.12883","article-title":"Disease-modifying treatments for multiple sclerosis - a review of approved medications","volume":"23","author":"Torkildsen","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104169_bib0030","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.amepre.2015.09.026","article-title":"Breast cancer in young women: health state utility impacts by race\/ethnicity","volume":"50","author":"Trogdon","year":"2016","journal-title":"Am. J. Prev. Med."},{"issue":"1\u20132","key":"10.1016\/j.msard.2022.104169_bib0032","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jns.2008.02.009","article-title":"Clinical characteristics of multiple sclerosis in Lebanon","volume":"270","author":"Yamout","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2022.104169_bib0031","unstructured":"World Health Organization (WHO). Global Health Observatory data repository. Life tables by country - Lebanon. 2018. Available from: https:\/\/apps.who.int\/gho\/data\/view.main.60910?lang=en."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:34Z","timestamp":1761901474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822006757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":32,"alternative-id":["S2211034822006757"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104169","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104169"}}